American Association for Cancer Research
00085472can183441-sup-211457_2_supp_5379502_pnfypf.xlsx (52.72 kB)

Supplementary File 3 from Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma

Download (52.72 kB)
posted on 2023-03-31, 03:08 authored by Mary Hoffman, Aaron H. Gillmor, Daniel J. Kunz, Michael J. Johnston, Ana Nikolic, Kiran Narta, Mehdi Zarrei, Jennifer King, Katrina Ellestad, Ngoc Ha Dang, Florence M.G. Cavalli, Michelle M. Kushida, Fiona J. Coutinho, Yuankun Zhu, Betty Luu, Yussanne Ma, Andrew J. Mungall, Richard Moore, Marco A. Marra, Michael D. Taylor, Trevor J. Pugh, Peter B. Dirks, Douglas Strother, Lucie Lafay-Cousin, Adam C. Resnick, Stephen Scherer, Donna L. Senger, Benjamin D. Simons, Jennifer A. Chan, A. Sorana Morrissy, Marco Gallo

Summary of somatic and de novo germline events.


Canadian Institutes of Health Research


Wellcome Trust





Pediatric glioblastoma (pGBM) is a lethal cancer with no effective therapies. To understand the mechanisms of tumor evolution in this cancer, we performed whole-genome sequencing with linked reads on longitudinally resected pGBM samples. Our analyses showed that all diagnostic and recurrent samples were collections of genetically diverse subclones. Clonal composition rapidly evolved at recurrence, with less than 8% of nonsynonymous single-nucleotide variants being shared in diagnostic-recurrent pairs. To track the origins of the mutational events observed in pGBM, we generated whole-genome datasets for two patients and their parents. These trios showed that genetic variants could be (i) somatic, (ii) inherited from a healthy parent, or (iii) de novo in the germlines of pGBM patients. Analysis of variant allele frequencies supported a model of tumor growth involving slow-cycling cancer stem cells that give rise to fast-proliferating progenitor-like cells and to nondividing cells. Interestingly, radiation and antimitotic chemotherapeutics did not increase overall tumor burden upon recurrence. These findings support an important role for slow-cycling stem cell populations in contributing to recurrences, because slow-cycling cell populations are expected to be less prone to genotoxic stress induced by these treatments and therefore would accumulate few mutations. Our results highlight the need for new targeted treatments that account for the complex functional hierarchies and genomic heterogeneity of pGBM. This work challenges several assumptions regarding the genetic organization of pediatric GBM and highlights mutagenic programs that start during early prenatal development.